+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Conjugate Vaccine Market by Product Type, Carrier Protein Type, Technology, Application, Distribution Channel, End User - Global Forecast 2026-2032- Product Image
Conjugate Vaccine Market by Product Type, Carrier Protein Type, Technology, Application, Distribution Channel, End User - Global Forecast 2026-2032- Product Image
Sale

Conjugate Vaccine Market by Product Type, Carrier Protein Type, Technology, Application, Distribution Channel, End User - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896495
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Conjugate Vaccine Market is projected to reach USD 20.85 Billion in 2026. It is expected to continue growing at a CAGR of 7.52%, reaching USD 32.33 Billion by 2032.

Conjugate vaccines are a cornerstone of modern immunization because they link bacterial polysaccharides to carrier proteins, converting weak T-cell-independent responses into durable T-cell-dependent immunity with immune memory. This mechanism is especially important for infants and young children and underpins licensed vaccines against Haemophilus influenzae type b, pneumococcal disease, meningococcal disease, and typhoid.

The conjugate vaccine market is being shaped by expanded national immunization programs, catch-up campaigns, rising antimicrobial resistance concerns, and continued demand for pediatric, adolescent, adult, and travel vaccines. For manufacturers, public health agencies, and investors, the most important growth signals are product differentiation by serotype coverage, reliable supply, regional procurement policy, cold-chain readiness, WHO prequalification where relevant, and evidence demonstrating real-world reductions in invasive bacterial disease.

Transformative Shifts in the Conjugate Vaccine Landscape

The conjugate vaccine landscape is shifting from single-pathogen prevention toward broader portfolio strategies that address invasive bacterial disease across life stages. Higher-valency pneumococcal conjugate vaccines, meningococcal combination approaches, and typhoid conjugate vaccine introductions are redefining competition by emphasizing broader coverage, simplified schedules, and programmatic efficiency.

Public procurement is also changing the market. UNICEF, Gavi-supported programs, national immunization technical advisory groups, and regional tenders increasingly prioritize affordability, supply assurance, WHO prequalification where relevant, and post-introduction surveillance. At the same time, manufacturers are investing in scalable conjugation chemistry, carrier protein optimization, analytical characterization, and fill-finish resilience to reduce supply disruptions and improve access in both high-income and emerging markets.

Cumulative Impact of Artificial Intelligence on Conjugate Vaccines

Artificial intelligence is beginning to influence the conjugate vaccine value chain, although adoption remains governed by strict validation, quality, and regulatory expectations. AI-enabled analytics can support antigen selection, epitope mapping, process development, stability modeling, batch-release trend analysis, and signal detection in pharmacovigilance databases when supported by high-quality, traceable data.

The cumulative impact is likely to be operational rather than purely experimental in the near term. Companies that combine AI with validated laboratory workflows, good manufacturing practice controls, and transparent model governance can shorten development learning cycles, improve yield consistency, and strengthen safety monitoring. However, AI outputs must remain explainable, auditable, and aligned with FDA, EMA, WHO, and national regulatory expectations for biological products.

Key Regional Insights for Conjugate Vaccines

Asia-Pacific is a high-priority region because of large birth cohorts, expanding immunization budgets, domestic vaccine manufacturing capacity, and sustained demand for pediatric protection against pneumococcal, meningococcal, Hib, and typhoid disease. China, India, Japan, South Korea, and Australia show different adoption patterns, ranging from domestic production scale-up and regulatory modernization to advanced lifecycle management, adult risk-based vaccination, and travel-related vaccine demand.

North America remains an innovation-led region supported by CDC and national advisory recommendations, mature pediatric schedules, adult risk-based vaccination, school-entry requirements in some jurisdictions, and strong pharmacovigilance infrastructure. Europe benefits from national immunization programs, EMA-regulated quality standards, evidence-based health technology assessment, and broad public health acceptance, while Latin America continues to rely on national procurement, PAHO-linked purchasing mechanisms, and catch-up campaigns to improve equitable access to conjugate vaccines.

The Middle East is influenced by government-funded immunization, pilgrimage-related meningococcal vaccination requirements, and health system modernization across GCC countries. Africa remains central to global access strategies because conjugate vaccines can substantially reduce disease burden where invasive bacterial disease surveillance, cold-chain strengthening, and routine immunization coverage are priorities, particularly through partnerships involving WHO, Gavi, UNICEF, and national ministries of health.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are advancing through routine immunization expansion, regional procurement learning, and growing investment in cold-chain capacity, with typhoid and pneumococcal disease prevention remaining important public health considerations in several member states. The GCC prioritizes high-quality imported vaccines, national schedule modernization, and meningococcal vaccination linked to travel and pilgrimage health requirements. The European Union is shaped by centralized regulatory standards, national reimbursement decisions, joint public health coordination, and safety monitoring through European pharmacovigilance systems.

BRICS countries are strategically important due to large populations, public-sector vaccine demand, infectious disease prevention priorities, and rising domestic manufacturing ambitions, especially in China, India, Brazil, Russia, and South Africa. G7 markets remain critical for premium conjugate vaccine innovation, higher-valency product launches, clinical evidence generation, and real-world effectiveness studies. NATO countries overlap with many high-income immunization systems, where preparedness, secure supply chains, and resilient medical countermeasure infrastructure are increasingly important policy considerations for vaccine availability and continuity.

Key Country Insights for Major Conjugate Vaccine Markets

The United States leads in conjugate vaccine innovation through established ACIP recommendations, advanced clinical development, and strong uptake in pediatric programs, while Canada emphasizes publicly funded immunization and evidence-based schedule decisions. Mexico and Brazil are important Latin American markets where public procurement and national immunization programs shape access, with Brazil also maintaining strong public-sector vaccine capabilities and surveillance-linked immunization policy.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on national immunization authorities, reimbursement frameworks, and disease surveillance systems to determine schedule design and product adoption. Russia remains relevant through domestic vaccine policy, localized production priorities, and national immunization planning. China is expanding domestic vaccine capabilities and regulatory modernization, while India combines large disease-prevention needs, major manufacturing capacity, and increasing use of conjugate technologies, including typhoid conjugate vaccination in relevant settings.

Japan, Australia, and South Korea are high-standard markets with rigorous regulatory review, mature pediatric schedules, strong safety monitoring, and active assessment of serotype replacement and invasive disease trends. Across these countries, competitive advantage depends on serotype coverage, safety evidence, supply reliability, public tender performance, physician confidence, cold-chain execution, and demonstrated impact on invasive disease and antimicrobial resistance reduction.

Actionable Recommendations for Conjugate Vaccine Industry Leaders

Industry leaders should prioritize differentiated conjugate vaccine pipelines that address clear epidemiological needs, including broader pneumococcal serotype coverage, meningococcal protection, typhoid prevention, and combination strategies that reduce schedule complexity. Investment in real-world effectiveness studies, disease surveillance partnerships, immunogenicity bridging evidence, and health economics data can strengthen payer confidence and national immunization decisions.

Manufacturers should also build resilient supply networks, diversify critical raw materials, strengthen quality control, and expand fill-finish capacity to meet tender obligations. AI and automation should be adopted with robust validation, cybersecurity, and regulatory documentation. Commercial teams should align pricing, access, and procurement strategies to country income levels, public health priorities, cold-chain capacity, and WHO prequalification requirements where global tenders are essential.

Research Methodology for Conjugate Vaccine Market Analysis

This executive summary is based on structured secondary research and market triangulation using public health guidance, regulatory information, peer-reviewed literature, vaccine pipeline disclosures, procurement patterns, disease surveillance findings, and national immunization schedules. Priority sources include WHO, UNICEF, Gavi, CDC, FDA, EMA, national health ministries, regional public health agencies, and recognized scientific publications covering conjugate vaccine safety, effectiveness, manufacturing, and access.

The analysis evaluates demand drivers, regional policy environments, technology trends, competitive positioning, and adoption barriers. Insights were cross-checked for consistency across public datasets and authoritative institutional sources, with emphasis on verified evidence rather than speculative market claims. The methodology supports executive communication while preserving public health accuracy and industry relevance.

Conclusion: Strategic Outlook for Conjugate Vaccines

Conjugate vaccines will remain essential to global infectious disease prevention because they deliver durable immune responses against encapsulated bacteria and can reduce severe disease, transmission, and antibiotic use. Market momentum is supported by routine immunization expansion, higher-valency innovation, typhoid conjugate vaccine adoption, stronger public procurement systems, and continued focus on antimicrobial resistance prevention.

The next phase of competition will reward organizations that combine scientific differentiation with equitable access, manufacturing reliability, regulatory excellence, and real-world evidence. Stakeholders that align product development with regional disease burden, national immunization priorities, WHO guidance, and resilient supply strategies will be best positioned in the evolving conjugate vaccine market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Conjugate Vaccine Market, by Product Type
7.1. HIB Conjugate Vaccine
7.2. Meningococcal Conjugate Vaccine
7.3. Pneumococcal Conjugate Vaccine
8. Conjugate Vaccine Market, by Carrier Protein Type
8.1. Tetanus Toxoid
8.2. Diphtheria Toxoid
8.3. Outer Membrane Protein Complex
9. Conjugate Vaccine Market, by Technology
9.1. Chemical Conjugation
9.2. Protein Conjugation Technology
9.3. Recombinant Conjugate Vaccines
10. Conjugate Vaccine Market, by Application
10.1. Respiratory Infections
10.2. Meningitis
10.3. Gastrointestinal Infections
10.4. Sepsis/Bacteremia
11. Conjugate Vaccine Market, by Distribution Channel
11.1. Offline
11.2. Online
12. Conjugate Vaccine Market, by End User
12.1. Clinics
12.2. Hospitals
13. Asia-Pacific Conjugate Vaccine Market
14. Europe Conjugate Vaccine Market
15. North America Conjugate Vaccine Market
16. Latin America Conjugate Vaccine Market
17. Africa Conjugate Vaccine Market
18. Middle East Conjugate Vaccine Market
19. NATO Conjugate Vaccine Market
20. G7 Conjugate Vaccine Market
21. European Union Conjugate Vaccine Market
22. BRICS Conjugate Vaccine Market
23. ASEAN Conjugate Vaccine Market
24. GCC Conjugate Vaccine Market
25. United States Conjugate Vaccine Market
26. China Conjugate Vaccine Market
27. Germany Conjugate Vaccine Market
28. Japan Conjugate Vaccine Market
29. India Conjugate Vaccine Market
30. United Kingdom Conjugate Vaccine Market
31. France Conjugate Vaccine Market
32. Canada Conjugate Vaccine Market
33. Italy Conjugate Vaccine Market
34. Australia Conjugate Vaccine Market
35. South Korea Conjugate Vaccine Market
36. Brazil Conjugate Vaccine Market
37. Mexico Conjugate Vaccine Market
38. Russia Conjugate Vaccine Market
39. Spain Conjugate Vaccine Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Bharat Biotech International Ltd.
41.2. Biological E. Limited
41.3. CanSino Biologics Inc.
41.4. CSL Limited
41.5. Dynavax Technologies Corporation
41.6. Emergent BioSolutions Inc.
41.7. GlaxoSmithKline plc
41.8. Indian Immunologicals Limited
41.9. Inventprise Inc.
41.10. Merck & Co., Inc.
41.11. Panacea Biotec Ltd.
41.12. Pfizer Inc.
41.13. Sanofi S.A.
41.14. Serum Institute of India Pvt. Ltd.
41.15. Sinopharm Group Co., Ltd.
41.16. Sinovac Biotech Ltd.
41.17. SK bioscience Co., Ltd.
41.18. Takeda Pharmaceutical Company Limited
41.19. Valneva SE
41.20. Vaxcyte, Inc.
41.21. Walvax Biotechnology Co., Ltd.
41.22. Wuhan Institute of Biological Products
41.23. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL CONJUGATE VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CONJUGATE VACCINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CONJUGATE VACCINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CONJUGATE VACCINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CHINA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. GERMANY CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. JAPAN CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. INDIA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. CANADA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. BRAZIL CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. MEXICO CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. RUSSIA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CONJUGATE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL HIB CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL HIB CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL HIB CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MENINGOCOCCAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MENINGOCOCCAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MENINGOCOCCAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PNEUMOCOCCAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PNEUMOCOCCAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PNEUMOCOCCAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL TETANUS TOXOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL TETANUS TOXOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TETANUS TOXOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DIPHTHERIA TOXOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DIPHTHERIA TOXOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DIPHTHERIA TOXOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL OUTER MEMBRANE PROTEIN COMPLEX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL OUTER MEMBRANE PROTEIN COMPLEX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL OUTER MEMBRANE PROTEIN COMPLEX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CHEMICAL CONJUGATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CHEMICAL CONJUGATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CHEMICAL CONJUGATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PROTEIN CONJUGATION TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PROTEIN CONJUGATION TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PROTEIN CONJUGATION TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RECOMBINANT CONJUGATE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RECOMBINANT CONJUGATE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RECOMBINANT CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MENINGITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MENINGITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MENINGITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GASTROINTESTINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GASTROINTESTINAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GASTROINTESTINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SEPSIS/BACTEREMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL SEPSIS/BACTEREMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SEPSIS/BACTEREMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 72. EUROPE CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. EUROPE CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 74. EUROPE CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 75. EUROPE CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 76. EUROPE CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 77. EUROPE CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 78. EUROPE CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 93. AFRICA CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. AFRICA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 95. AFRICA CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 96. AFRICA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 97. AFRICA CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 98. AFRICA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 99. AFRICA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. NATO CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. NATO CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 109. NATO CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 110. NATO CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 111. NATO CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 112. NATO CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. NATO CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. G7 CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. G7 CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 116. G7 CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 117. G7 CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 118. G7 CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 119. G7 CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. G7 CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. EUROPEAN UNION CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 123. EUROPEAN UNION CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. BRICS CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. BRICS CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 130. BRICS CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 131. BRICS CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 132. BRICS CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 133. BRICS CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. BRICS CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. ASEAN CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. ASEAN CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 137. ASEAN CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 138. ASEAN CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 139. ASEAN CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 140. ASEAN CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. ASEAN CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. GCC CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GCC CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 144. GCC CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 145. GCC CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 146. GCC CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 147. GCC CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. GCC CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. UNITED STATES CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 150. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 151. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 152. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 153. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. CHINA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 157. CHINA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 158. CHINA CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 159. CHINA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 160. CHINA CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. CHINA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. CHINA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. GERMANY CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 164. GERMANY CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 165. GERMANY CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 166. GERMANY CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 167. GERMANY CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 168. GERMANY CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. GERMANY CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. JAPAN CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 171. JAPAN CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 172. JAPAN CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 173. JAPAN CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 174. JAPAN CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 175. JAPAN CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. JAPAN CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. INDIA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 178. INDIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 179. INDIA CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 180. INDIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 181. INDIA CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 182. INDIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 183. INDIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 186. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 187. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 188. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 189. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. FRANCE CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 192. FRANCE CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 193. FRANCE CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 194. FRANCE CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 195. FRANCE CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 196. FRANCE CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 197. FRANCE CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. CANADA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 199. CANADA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 200. CANADA CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 201. CANADA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 202. CANADA CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 203. CANADA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. CANADA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. ITALY CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 206. ITALY CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 207. ITALY CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 208. ITALY CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 209. ITALY CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 210. ITALY CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 211. ITALY CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 213. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 214. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 215. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 216. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 217. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 220. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 221. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 222. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 223. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 224. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. BRAZIL CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 228. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 229. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 230. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 231. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 232. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. MEXICO CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 234. MEXICO CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 235. MEXICO CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 236. MEXICO CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 237. MEXICO CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 238. MEXICO CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. MEXICO CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. RUSSIA CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 241. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 242. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 243. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 244. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 245. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 246. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. SPAIN CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 248. SPAIN CONJUGATE VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 249. SPAIN CONJUGATE VACCINE MARKET SIZE, BY CARRIER PROTEIN TYPE, 2018-2032 (USD MILLION)
TABLE 250. SPAIN CONJUGATE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 251. SPAIN CONJUGATE VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 252. SPAIN CONJUGATE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 253. SPAIN CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Conjugate Vaccine market report include:
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • CanSino Biologics Inc.
  • CSL Limited
  • Dynavax Technologies Corporation
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Indian Immunologicals Limited
  • Inventprise Inc.
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Sinopharm Group Co., Ltd.
  • Sinovac Biotech Ltd.
  • SK bioscience Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Vaxcyte, Inc.
  • Walvax Biotechnology Co., Ltd.
  • Wuhan Institute of Biological Products
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 20.85 Billion
Forecasted Market Value ( USD ) by 2032 $ 32.33 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Pneumococcal 13-valent Conjugate Vaccine Market - Global Forecast 2026-2032 - Product Image

Pneumococcal 13-valent Conjugate Vaccine Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Conjugate Vaccines - Global Strategic Business Report - Product Image

Conjugate Vaccines - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Conjugate Vaccine Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Conjugate Vaccine Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 182 Pages
  • Global
From
Conjugate Vaccine Market Report 2026 - Product Image

Conjugate Vaccine Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Conjugate Vaccine Market

The Conjugate Vaccine market is a subset of the Vaccines market, which is composed of products designed to prevent and treat infectious diseases. Conjugate Vaccines are a type of vaccine that combines a polysaccharide antigen with a protein carrier, which helps the body to recognize the antigen and mount an immune response. These vaccines are used to protect against a variety of bacterial infections, including meningitis, pneumonia, and sepsis. Conjugate Vaccines are typically administered to infants and young children, as their immune systems are not yet fully developed and are more susceptible to certain infections. In addition, these vaccines are often used in combination with other vaccines to provide broader protection against multiple diseases. Notable companies in the Conjugate Vaccine market include GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.